Lupin Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Margin expansion with R&D ramp: EBITDA margin improved 510 bps YoY to the 22–23% range even as R&D spend rose 190 bps sequentially to 8.2% of sales, a combination that signals operating leverage is kicking in.
• US business is now the margin leader: US profitability has moved above the corporate average, driven by a richer product mix and a deliberate shift toward complex generics, now 40% of the portfolio with a target of 50%+ in two years.
• India formulations ran 40% ahead of the market: 10.9% growth with every major therapy area outpacing its category, and the diabetes portfolio rebounded to 19% growth after past LOE headwinds.
• The pipeline is deep but the clock is ticking on injectables: Glucagon and Dalbavancin are expected in the next couple of quarters, but one may slip into Q1 next year; Risperidone and Liraglutide are pushed to next fiscal year, making near-term US growth dependent on in-line volume and Mirabegron.
• What to watch next quarter: Whether the two injectables approvals actually land in Q4, the pace of Medicare-Medicaid conversion for Spiriva toward the mid-30s share target, and any lumpiness from the tender business that could swing India region revenue.

US Business: The Margin Engine

• Volume-led growth, price still a drag: In-line products and the respiratory portfolio drove volumes, offset by low single-digit price erosion and additional competition in Suprep and Doxycycline. Channel inventory loading for some new launches is expected to normalize.
• Mirabegron 50mg launch: The 25mg strength saw inventory load in Q1; the 50mg launch involved more substitution and less channel fill, so phasing will normalize in H2. Respiratory portfolio and Mirabegron share continued to build through Q2.
• Spiriva share stuck at 30%: Over 50% share in the commercial channel but materially lower in Medicare-Medicaid, pulling the blended number down. Management is working to drive conversion in the government channel over the next couple of quarters toward the mid-30s.
• US margins now exceed corporate average: Newer complex products with limited competition have structurally expanded US profitability. The base business is described as fairly strong.
• Second-half confidence: Management expects the US business to close the fiscal year at double-digit growth and reach a USD 250 million quarterly run-rate next year, putting it on a USD 1 billion+ annual trajectory.

Vinita Gupta: "So far, we have evolved our business to 40% complex generics, and we have an exciting pipeline with more than 20 respiratory products, and 40 injectable products in development that we believe will enable us to continue to drive the shift to 50% plus in the next couple of years."

Margin Structure & Levers

• 510 bps YoY EBITDA expansion: The improvement came despite a 190 bps sequential increase in R&D spend and higher employee costs from annual increments, ESOP charges tied to the rising share price, and new hires.
• Gross margin drivers, three-pronged: Product mix (Mirabegron contribution), declining procurement costs expected to continue falling, and operational efficiencies including alternate vendor development and a shift from air to ocean freighting.
• Adjacencies are a 0.8% drag: Diagnostics, digital, and parts of OTC remain loss-making. Management intends to spin these off with private equity participation in the next couple of years, at which point they should operate on their own axis.
• One-off items in the quarter: Other operating income rose INR 76 crore, PLI income was higher due to an export surge but is not a run-rate, and a INR 58 crore provision was taken for litigation/disputes described as abundant caution and not expected to repeat.
• Medium-term margin ambition: Core EBITDA margin is targeted at 23–25% in the medium term, with the overall business expanding from the current 23% level to the mid-20s and above over five years.

Ramesh Swaminathan: "Obviously, we believe that our core should be in the range of about 23% - 25% and that is something that we would get to in the medium term."

India & Emerging Markets

• India formulations grew 10.9%, 40% ahead of market: Cardiac, Respiratory, Diabetes, and GI all grew ahead of their categories. The diabetes portfolio rebounded from past LOE challenges to grow 19% YoY against a category growth of 9%.
• India region revenue up 19% YoY: The jump was led by India formulations plus additional tenders in Global Institutional Business. Adjacencies and domestic GIB contributed INR 208 crores versus INR 66 crores in Q2 last year.
• Tender business is profitable but lumpy: Tenders are sporadic by nature; India tenders were delayed for a couple of years. The latent TB opportunity sits with the Global Fund and the market is roughly USD 650 million. Management expects tender revenue to stay at current levels for the year with possible lumpiness.
• Sales force productivity still ramping: Current productivity is approximately INR 7.5 lakhs per month per representative, increasing but not yet at peak due to training and teething for new hires. The company will add a few hundred representatives each year while deploying AI tools to lift productivity.
• Emerging markets: Healthy growth in Mexico and South Africa. GLP-1 products are positioned for launch in India, South Africa, Latin America, the Philippines, and parts of Eastern Europe starting in 2026.

Pipeline: Complex Generics, Injectables & Biosimilars

• Ranibizumab biosimilar: Phase 3 completed successfully; US and EU filing expected by end of fiscal year 2025. Not a first-wave launch, but management expects decent size given existing ophthalmic relationships.
• Injectables timeline, near-term slippage risk: Glucagon and Dalbavancin are expected in the next couple of quarters, but management flagged that one may land in Q4 and one might slip into Q1 of next year. Risperidone and Liraglutide (Victoza) are both pushed to next fiscal year.
• Respiratory pipeline, no revenue before FY27: Dulera requires additional studies to respond to the agency, with a hoped-for FY27–28 opportunity. Respimat and Ellipta products need exhibit batches before fiscal year-end and patent certification, so launches are not expected before 2027.
• GLP-1 strategy spans geographies and timelines: India and select emerging markets open in 2026; regulated developed markets lose exclusivity around 2030 except Canada. Manufacturing capacity is sufficient to supply every market opening in 2026 from internal facilities. The portfolio combines internal development and in-licensing.
• Specialty build, cautious and acquisitive: A new president has been onboarded with a focus on respiratory and neurology. The strategy targets medium-sized acquisitions of USD 100–200 million assets, building a bouquet of 3–4 products over 3–5 years, with an emphasis on accretive assets that do not dilute the margin expansion path.
• NaMuscla for myotonic dystrophy: A study is underway with FDA feedback received; US filing expected in 2026, commercialization likely in fiscal 2028, with Europe likely first. Management sees USD 100 million potential in Europe and well beyond that in the US depending on pricing.

Vinita Gupta: "Injectables right now are a very small part of our portfolio so were looking forward to these approvals. We expect Glucagon and Dalbavancin in the next couple of quarters. One may be in Q4 and I think one might slip into Q1 of next year."

Strategic Bets: CDMO & Capital Allocation

• Lupin Manufacturing Solutions (CDMO subsidiary): A new entity has been created and the leadership team is being assembled, with the full structure expected to fall in place between this quarter and next. Management asks for a year or two of execution before drawing conclusions but is very optimistic.
• Capital allocation actively under review: The company is exploring strategic deployment of capital to support long-term growth, though no specific transactions were disclosed. The specialty acquisition strategy and CDMO build are the visible priorities.
• Biosimilar commercialization, partner-where-it-makes-sense: Denosumab is partnered in Japan with no plans for other markets without a partner. Etanercept US launch is not expected until 2029. The approach is cautious: leverage existing infrastructure where synergy exists, partner where it does not.

Nilesh Gupta: "Obviously, it's early days, we're putting the team together. I think we've got almost all the entire structure that will fall in place between this quarter and the next quarter. And then obviously, I think we need to put our head down and give it a year or two years of good work to be able to talk about this."

Guidance & Commitments

Key Metrics